Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Disease
- Therapeutic
- Drug Discovery
- cardiac
- Diabetes Treatment
- obesity
- Pharmaceuticals
- Alzheimer’s disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 245875
BACE Collaboration Compound means a compound that is a BACE Inhibitor, and is discovered by either or both Parties or their Affiliates during the Research Term, or is acquired by either or both Parties or their Affiliates during the Research Term, or was discovered by Licensor prior to the Research Term. BACE Collaboration Compounds discovered prior to the Effective Date by Licensor.
BACE Inhibitor means a compound that at Licensor inhibits human BACE enzyme activity by fifty percent (50%) at a concentration (IC50) of less than one micromole per liter ( <l µmol/L) in an in vitro assay in which the Licensor inhibitor standard, I-!4848, has an ICso of less than fifteen nanomoles per liter (<15 nmoVL) in an assay following the protocol as currently performed at Vitae and/or a compound that at Licensee inhibits human BACE enzyme activity by fifty percent (50%) at an ICso of less than one micromole per liter (<l µmol/L) in in vitro assays in which the Licensee standard inhibitor, N-((1S,2R)-1-benzyl-3- cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino )-N-( (R)-1-phenylethyl)-isophthalamide (compound 3 from Stachel et al. J. Med. Chem. 2004, 47, 6447-6450) has an IC50 of less than or equal to seventy nanomoles per liter (s70 nmol/L) in assays following the protocols as currently performed at Licensee.
Licensee is responsible for the development and commercialization of BACE inhibitors for the treatment of Alzheimer's disease and other forms of dementia.
IPSCIO Record ID: 245876
This agreement includes a non-exclusive grant back to Licensor.
IPSCIO Record ID: 299249
Licensor grants, commencing at the expiration of the Research Term and for a period of six years thereafter, a non-exclusive, world-wide right and license under the Licensor Patents and Licensor Know-How, and Licensors rights in the Joint Patents and Joint Know-How, solely to discover, synthesize, and, in connection with Licensees activities under this Agreement, make and use Active Compounds for use in the Field.
For the Commercialization License to Licensee, Licensor grants an exclusive, world-wide right and license under the Licensor Patents, the Licensor Know-How and under Licensors rights in the Joint Know-How and Joint Patents, solely to [conduct development on, and to make, have made and use for such purpose, Back-Up Compounds and Collaboration Compounds for use in the Field and to make, have made, import, use, sell and offer for sale Licensed. Products) for use in the Field.
For the Cross-License of Know-How Licensor grants a non-exclusive license under the Licensor Know-How for any purpose or use.
Licensed Product means any product, including any formulation thereof, containing or comprising a Collaboration Compound.
Active Compound means any compound that
— has the ability to inhibit (or, in the case of a prodrug, an active species of which inhibits) cathepsin S with a [K; equal to or less than 100 nM];
— has greater than [100- fold selectivity] for cathepsin S against an [appropriate panel of cathepsins in appropriate assays,] as determined by the JRC; and
— has appropriate [in-cell activity in concentrations of less than IO µMin a relevant cell based assay(s)] selected by the JRC.
Cathepsin S is associated with certain inflammatory diseases, such as arthritis, asthma, atherosclerosis and a variety of autoimmune diseases.
Cysteine proteases are enzymes that are responsible for the cleavage and breakdown of other natural proteins in normal biological processes. In disease conditions, cystein proteases can often be misregulated, providing an entry point for drug intervention. Cathepsin S has been associated with the processing and activation of the antigen receptor called MHC-II, essential for the initiation of both normal and pathological immune responses mediated by T-cells. Drugs designed to inhibit this enzyme may provide a novel method for control of antigen-induced response in multiple inflammatory and autoimmune disease states, the companies believe.
IPSCIO Record ID: 24743
Licensor desires to grant an exclusive license under Licensor Exclusively Licensed IP to make, have made, use, sell, offer for sale and import Products throughout the Territory.
To facilitate the Research Collaboration, either Party the Transferor, shall upon request by the other Party provide the other Party certain biological materials or chemical compounds, such as cell based assays or research tools owned by or licensed to the Transferor.
For the License at the time the Transferor provides Materials to the Recipient, the Transferor does grant to the Recipient, a non-exclusive license under the Material IP Controlled by the Transferor or its Affiliates to use such Materials for the purpose set forth in the Transfer Record.
For the Development And Commercialization, Licensor grants the exclusive right and license in the Territory, with the right to grant sublicenses, under the Licensor Exclusively Licensed IP, to make, have made, use, sell, offer for sale, import and otherwise exploit the Licensee Development Compounds and any Derivatives thereof as and into Products during the Term.
For Licensee's Derivatives Research, following Licensee's exercise of the PoC Option and the expiration or termination of the Research Collaboration Term, Licensor grants a non-exclusive, worldwide license under the Licensor Exclusively Licensed IP, commencing upon the expiration or termination of the Research Collaboration and continuing for the remainder of the Term, solely to conduct the research described.
Licensor has discovered five clinical compounds which are currently in development, including its three lead programs AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria.
Licensor's Exclusively Licensed IP means, collectively, Licensor's Compound IP with respect to the Licensee Development Compounds; Licensor's Target Patents; Licensor's Target KnowHow; Collaboration Compound IP with respect to the Licensee's Development Compounds that is owned or Controlled by Licensor on the Effective Date or at any time during the Term; Licensee's Development Compound IP owned or Controlled by Licensor on the Effective Date or at any time during the Term; and to the extent not included in the foregoing, Licensor's Patents with respect to the Licensee's Development Compounds or Products.
Licensor Compound means any small molecule compound that is generated or discovered by Licensor during the Term or is within Licensor's existing compound bank, is within the Field and is a Ribosomal Peptidyl Transferase Center inhibitor that displaces radioactive linezolid from P. acnes ribosomes (1µM) with an IC5O of 10 µMor less.
Antibiotic means a compound with a minimum inhibitory concentration (MIC) against P. acnes of less than 8 µg/ml.
Target means the Ribosomal Peptidyl Transferase Center (PTC) of the P. acnes ribosome.
This target indication is for acne.
IPSCIO Record ID: 239034
U.S. #1
(a) First US provisional filed January 22, 2001 (60/262,651).
(b) Second US provisional filed February 8, 2001 (60/267,196).
(c) Third US provisional filed July 19, 2001 (60/306,140)
(d) A regular US patent application (10/051,309) was filed on January 22, 2002, claiming priority to the above-mentioned three US provisional applications.
U.S. #2
(a) First US provisional filed February 8, 2001 (60/267,195)
(b) Second US provisional filed January 7, 2002 (60/344,824).
(c) A regular US patent application (10/067,996) was filed on February 8, 2002, claiming priority to the above-mentioned two US provisional applications.
(d) Possible Second US family to be filed; awaiting analysis from MPC.
U.S.#3
A first US provisional application (Memory 3 VI) was filed October 16, 2001 (60/329,314).
U.S. #4
(a) First US provisional filed November 15, 2001 (60/331,422)
(b) Second US provisional filed January 23, 2002 (60/349,985).
U.S. #5
(a) U.S. provisional application filed June 25, 1999 (60/141,196
(b) A regular U.S. Patent Application was filed June 23, 2000 (09/602,735), claiming priority to the above-mentioned provisional application.
Licensor Compound means any PDE4 inhibitor for which Licensor either prior to the Effective Date or during the Agreement Term has rights, whether by reason of its own conception of such inhibitor, or under agreement with a Third Party.
Collaboration Compound means any PDE4 inhibitor that (i) either or both Parties or its Affiliates conceives in the conduct of the Research Collaboration, or (ii) the JLT otherwise agrees shall constitute a Collaboration Compound pursuant to the Research Workplan.
'Neurological Indication' means prophylaxis or treatment of Alzheimers' disease, prophylaxis or treatment of mild cognitive impairment ('MCI') or treatment of vascular dementia.
'Non-Memory Compound' means a PDE4 inhibitor, other than a Memory Compound or a Collaboration Compound, with respect to which the initial IND for the inhibitor is for a Neurological Indication or Psychiatric Indication.
'Psychiatric Indication' means depression, anxiety or mixed anxiety/depression.
MEM 1917 is a PDE4 inhibitor that we are developing for the treatment of depression.
IPSCIO Record ID: 223130
Licensor hereby grants to Licensee a worldwide, exclusive license under Licensors interest in the Collaboration Technology to develop, make, have made, use, import, offer for sale, sell, have sold or otherwise exploit (i) Development Candidates for any and all purposes in the Field; and (ii) Licensee-Derived Compounds outside the Field; in each case, alone or as incorporated into a Product.
Licensor hereby grants to Licensee a worldwide, exclusive license under the Licensor Prior Aspartyl Protease Patents to develop, make, have made, use, import, offer for sale, sell, have sold or otherwise exploit Development Candidates for any and all purposes in the Field, alone or as incorporated into a Product.
Licensor hereby grants to Licensee a worldwide, non exclusive license (i) under the Licensor Core Technology and Licensor Know-How as reasonably necessary or useful to develop, make, have made, use, import, offer for sale, sell, have sold or otherwise exploit Development Candidates for any and all purposes in the Field, and (ii) under the Licensor Know-How as reasonably necessary or useful to develop, make, have made, use, import, offer for sale, sell, have sold or otherwise exploit Licensee-Derived Compounds outside the Field; in each case, alone or as incorporated into a Product. It is understood that the foregoing license under Licensor Core Technology shall not include the right to practice Licensor Core Technology to discover novel compositions outside the Field, and shall only include the right to exploit Development Candidates that are Licensor-Derived Compounds, or that are Licensee-Derived Compounds generated without the use of Licensor Core Technology in accordance with this Agreement.
Licensee Research Know-How shall mean any information or material, including, but not limited to, discoveries, processes, methods, protocols, formulas, data, non- patented inventions, know-how, and trade secrets of Licensee, made or developed (i) solely by Licensee personnel in the course of performing the Research Program; or (ii) solely by or under authority of Licensee personnel during the Exclusivity Period in the course of activities directed to the discovery, research or development of compounds for use in the Field.
Collaboration Technology shall mean all Research Patents and Research Know-How.
Development Candidate shall mean any Collaboration Compound that is approved by Licensee in its sole discretion as a Development Candidate.
Collaboration Compound shall mean any chemical entity that is a protein, small molecule, or other compound that is synthesized by the Parties pursuant to work conducted under the Research Program and during the Research Term and Derivatives (as defined below) synthesized by a Party or its Affiliates on behalf of a Party prior to the third (3rd) anniversary of the end of the Research Term, and shall include any Licensee-Derived Compound or Licensor-Derived Compound, as the case may be.
Licensor Prior Aspartyl Protease Patents shall mean all patents and patent applications controlled by Licensor as of the Effective Date that claim small molecule inhibitors of Aspartyl Proteases, together with any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions, supplementary protection certificates, and other governmental actions which extend any of the patent applications or patents listed, and any all foreign counterparts of any of the foregoing.
Licensor Prior Aspartyl Protease Patents
SU-2400 P1 – Aspartyl Protease Inhabitors
SU-2499 P2 – Aspartyl Protease Inhabitors
SU-2600 P1 – Constructs for Homogeneously Processed Preparations of Beta Site APP-Cleaving Enzyme
Licensor will contribute an initial series of small molecule inhibitors and apply its proprietary fragment-based drug discovery 'Tethering' technology, a process in which the target selects fragments with binding affinity for a specific region on the target surface, to discover additional novel series of small molecules. The initial target in the collaboration is BACE ;-amyloid precursor protein-cleaving enzyme), an enzyme that mediates the deposition of amyloid plaque in the brain.
The research collaboration agreement is to discover novel oral therapeutics for the treatment of Alzheimer's disease.
